# Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

> **NCT05016349** · PHASE3 · UNKNOWN · sponsor: **Mahmoud Ramadan mohamed Elkazzaz** · enrollment: 160 (estimated)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** All trans-retinoic acid
- **DRUG:** 13-Cis Retinoic Acid plus Tocopherol
- **DRUG:** Mifepristone
- **DRUG:** Cannabidiol
- **DRUG:** 9 cis retinoic acid
- **DRUG:** Tamoxifen
- **DRUG:** Standard therapy

## Key facts

- **NCT ID:** NCT05016349
- **Lead sponsor:** Mahmoud Ramadan mohamed Elkazzaz
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08
- **Primary completion:** 2021-10
- **Final completion:** 2021-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2021-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05016349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05016349, "Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05016349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*